Abstract: This invention provides a system for separating a field of view (FOV) of a scene imaged by a vision system camera assembly, in which a separating mirror assembly redirects a first optical path of at least a first optics with respect to at least a first image sensor in the camera assembly. A first reflecting assembly redirects the first optical path from the separating mirror toward a first FOV. The first optical path is extended free of splitting the image. The separating mirror assembly redirects a second optical path of a second optics with respect to a second image sensor in the camera assembly. A second reflecting assembly redirects the second optical path from the separating mirror toward a second FOV. The second optical path is extended free of splitting the image projected from the scene on the second image sensor.

Abstract: This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

Abstract: In some embodiments, a medicinal carrier device includes: one or more sections of thermal insulation positioned to form an internal space with an adjacent first side region and an adjacent second side region; a first panel including a first phase change material positioned within the first side region of the internal space, the first side region of a size and shape to firmly contain an integral number of portable cold packs in thermal contact with the first panel; and a second panel including a second phase change material positioned within the second side region of the internal space, the second side region of a size and shape to firmly contain an integral number of portable cold packs in thermal contact with the second panel.

Abstract: This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

Abstract: This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

Abstract: This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

Abstract: A refrigeration device includes a thermal transfer unit with an evaporative region, an adiabatic region, and a condensing region with a reversible valve attached to the adiabatic region. The device includes a container sealed around PCM, with a set of refrigeration coils of a compressor unit in thermal contact with the PCM. A storage region is in thermal contact with the evaporative region of the thermal transfer unit. A controller is operably connected to the reversible valve and the refrigeration compressor unit. The storage region can be used to store cold packs within a predetermined temperature range for medical outreach.

Abstract: In some embodiments, a medicinal carrier device includes: one or more sections of thermal insulation positioned to form an internal space with an adjacent first side region and an adjacent second side region; a first panel including a first phase change material positioned within the first side region of the internal space, the first side region of a size and shape to firmly contain an integral number of portable cold packs in thermal contact with the first panel; and a second panel including a second phase change material positioned within the second side region of the internal space, the second side region of a size and shape to firmly contain an integral number of portable cold packs in thermal contact with the second panel.

Abstract: This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

Abstract: This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

Abstract: A refrigeration device includes a thermal transfer unit with an evaporative region, an adiabatic region, and a condensing region with a reversible valve attached to the adiabatic region. The device includes a container sealed around PCM, with a set of refrigeration coils of a compressor unit in thermal contact with the PCM. A storage region is in thermal contact with the evaporative region of the thermal transfer unit. A controller is operably connected to the reversible valve and the refrigeration compressor unit. The storage region can be used to store cold packs within a predetermined temperature range for medical outreach.

Abstract: This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

Abstract: This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

Abstract: This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

Abstract: Methods for producing a biofuel are provided. Also provided are biocatalysts that convert a feedstock to a biofuel.

Abstract: Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-position to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with E. coli, where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.

Abstract: This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

Abstract: The present invention is directed to renewable compositions derived from fermentation of biomass, and integrated methods of preparing such compositions.

Abstract: The present invention in its various embodiments is directed to methods for preparing a renewable jet fuel blendstock, and blendstocks prepared by such methods, comprising fermenting a biomass-derived feedstock to form one or more C2-C6 alcohols such as isobutanol, catalytically dehydrate and oligomerize the alcohols to form higher molecular weight olefins (e.g., C8-C16 olefins), hydrogenating at least a portion of the higher molecular weight olefins to form a renewable jet fuel blendstock comprising C12 and C16 alkanes which meet or exceed the requirements of ASTM D7566-10a for hydroprocessed synthesized paraffinic kerosene (SPK).

Abstract: Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-position to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with E. coli, where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.